The IPD-pooled analysis results confirm that non-HER2-positive/HER2-negative advanced or metastatic GC or GEJC with a negative PD-L1 expression had no significant PFS benefit from first-line immunotherapy. Here, ERBB2 is linked to gastric cancer.